Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes

Diabetes

Volumn 48, Issue 3, 1999, Pages 623-627

  Pfohl, Martin ^a,b   Koch, Matthias ^a   Enderle, Markus D ^a   Kühn, Romed ^a   Füllhase, Jochen ^a   Karsch, Karl R ^a   Häring, Hans U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ALLELE; ARTICLE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0032974874     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.3.623     Document Type: Article

References (43)

1. Marenberg MEN, Risch N, Berkman LF, Floderus B, de-Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:1041-1046, 1994
2. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809, 1993
3. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM: Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Circulation 15:1156-1167, 1992
4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69-76, 1996
5. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154, 1991
6. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115:243-253, 1995
7. Hassett, CR, Richter J, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE: Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30:10141-10149, 1991
8. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76, 1993
9. Ruiz, J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P: Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872, 1995
10. Odawara M, Tachi Y, Yamashitya K: Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260, 1997
11. Serrato M, Marian AJ: A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008, 1995
12. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick H, Ehnholm C: The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98:883-885, 1996
13. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K: Paraoxenase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57:69-73, 1996
14. Sanghera DK, Saha N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073, 1997
15. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques Vidal P, Bard JM, Cambien F: The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126:299-303, 1996
16. World Health Organization: WHO Expert Committee on Diabetes Mellitus. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 640)
17. Lopes-Virella MF, Stone P, Ellis S, Colwell SA: Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 23:882-884, 1977
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
19. Emery AEH: Hardy-Weinberg equilibrium: the estimation of gene frequencies. In Metholology in Medical Genetics: An Introduction to Statistical Methods. Emery AEH, Ed. Edinburgh, U.K., Churchill Livingstone, 1976, p. 3-9
20. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569, 1997
21. Lander ES, Schork NJ: Genetic dissections of complex traits. Science 265:2037-2048, 1994
22. Lyons TJ, Li W, Wells-Knecht MC, Jokl R: Toxicity of mildly modified low density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 43:1090-1095, 1994
23. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF: Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabeted 37:1652-1657, 1988
24. Kobayashi K, Watanabe J, Umeda F, Nawata H: Glycation accelerates the oxidation of low density lipoprotein by copperions. Endocr J 42:461-465, 1995
25. Church DF, Pryor WA: The free radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 64:111-126, 1985
26. Chow CK, Thacker RR, Changeit C, Bridges RB, Rehm SR, Humble J, Turbek J: Lower levels of vitamin C and carotenes in plasma of cigarette smokers. J Am Coll Nutr 5:305-312, 1986
27. Princen HMG, van Poppel G, Vogelezang C, Buytenhek R, Kok FJ: Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: effect of cigarette smoking. Arterioscler Thomb 12:554-562, 1992
28. Scheffler E, Wiest E, Woehrle J, Otto I, Schulz I, Huber L, Ziegler R, Dresel HA: Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest Med 70:263-268, 1992
29. Nishio E, Watanabe Y: Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Comm 236:289-293, 1997
30. Mackness MI, Arrol S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 349:851-852, 1997
31. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60, 1998
32. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parino SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590, 1998
33. Nagano Y, Arai H, Kita T: High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci U S A 88:6457-6461, 1991
34. Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased link of cardiovascular disease in diabetes. J Clin Invest 99:62-66, 1997
35. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349, 1998
36. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62:36-44, 1998
37. Heinecke JW, Lusis AJ: Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis (Editorial). Am J Hum Genet 62:20-24, 1998
38. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 92:657-671, 1995
39. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
40. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39:1540-1545, 1996
41. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino KB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med 102:38-47, 1997
42. Haffher SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
43. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B: Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrin Metab 82:3373-3377, 1997